## Abstract ## Aim This analysis evaluated the tolerability profile of quetiapine using data from all comparative controlled studies in patients with schizophrenia or related disorders in the AstraZeneca clinical trials database, focusing on extrapyramidal symptoms (EPS). ## Methods Adverse even
Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms
β Scribed by Takahide Taniguchi; Satsuki Sumitani; Michitaka Aono; Junichi Iga; Sawako Kinouchi; Hirosi Aki; Mami Matsushita; Kyoko Taniguchi; Mami Tsuno; Kazunari Yamanishi; Masahito Tomotake; Yasuhiro Kaneda; Tetsuro Ohmori
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 91 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0885-6222
- DOI
- 10.1002/hup.801
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Replacement of antipsychotic drugs with quetiapine (QTP) was tried in a naturalistic setting in chronic schizophrenic patients who still showed moderate psychiatric symptoms and either showed extrapyramidal symptoms (EPS) or took antiβparkinson drugs for the EPS. QTP was added on and gradually increased while the previous drugs were tapered and discontinued whenever possible. Clinical symptoms, objective and subjective QOL, and EPS were measured before and 6 months after QTP addition, using Brief Psychiatric Rating Scale (BPRS), Quality of Life Scale (QLS), Schizophrenia Quality of Life Scale (SQLS) and DrugβInduced Extrapyramidal Symptom Scale (DIEPSS), respectively. Twentyβone patients completed the trial and received the assessment. It was found that replacement with QTPβimproved clinical symptoms, objective and subjective QOL and EPS. This improvement was equally observed in not only patients who switched to QTP monotherapy (nβ=β11) but also patients who took QTP together with reduced small doses (4.4βΒ±β4.3βmg/day) of previous drugs (nβ=β11). The results suggest that replacement with QTP improves symptoms as well as objective and subjective QOL in a subgroup of schizophrenia. Copyright Β© 2006 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
## Abstract ## Objectives The present study investigated whether anxiety and depressive symptomatology moderates the relationship between age and quality of life. ## Methods The study was a communityβbased survey using mailed questionnaires conducted within the Department of Psychology at Washin
This analysis of data from the open-label extension (OLE) phases of three randomized clinical trials of quetiapine in patients with schizophrenia (n=415) was undertaken to investigate whether the initial improvements in anxiety and depressive symptoms were maintained during long-term treatment. The
## Abstract Negative symptoms are considered the most debilitating and refractory aspect of schizophrenia, being associated with poor social, occupational and global outcomes. Conventional antipsychotics have limited efficacy against these symptoms and poor tolerability profiles. Atypical antipsych